Literature DB >> 17234649

The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis.

László Czirják1, Zoltán Nagy, Martin Aringer, Gabriela Riemekasten, Marco Matucci-Cerinic, Daniel E Furst.   

Abstract

OBJECTIVE: To evaluate the ability to teach scleroderma experts and young rheumatologists to perform the modified Rodnan skin score test.
METHODS: Three international "teaching courses for teachers" were conducted with 6-9 experts who performed 3-9 skin score tests each. In addition, an international course for 90 young rheumatologists, in which 18 patients with systemic sclerosis (SSc) participated, was also organised. Finally, a local repeated training course for 5-9 rheumatologists was performed, in which 6-7 patients with SSc participated.
RESULTS: When 6-9 scleroderma specialists investigated the patients, the intraclass correlation coefficient (ICC) showed "good" to "excellent" values (0.865 and 0.710, respectively). When 90 young rheumatologists were involved in one teaching course, the coefficient of variation (CV) was relatively satisfactory (35%) owing to the high number of investigators, and with a considerable within-patient SD value of 5.4. Repeated teaching of 5-9 young rheumatologists in local courses clearly improved the consistency. The ICC increased from 0.496 to a "good" level of 0.722. The within-patient SD values for intraobserver variability ranged between 2.5 and 2.9. The intraobserver CV was about 20%.
CONCLUSIONS: This study strongly supports the need for standardisation among different centres when using skin scoring for clinical trials. The intraobserver variability and within-patient SD values can be significantly reduced by repeated teaching. For inexperienced rheumatologists, at least one repeated teaching course is needed.

Entities:  

Mesh:

Year:  2007        PMID: 17234649      PMCID: PMC1955103          DOI: 10.1136/ard.2006.066530

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

1.  Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group.

Authors:  P Brennan; A Silman; C Black; R Bernstein; J Coppock; P Maddison; T Sheeran; C Stevens; F Wollheim
Journal:  Br J Rheumatol       Date:  1992-07

Review 2.  Intraclass correlations: uses in assessing rater reliability.

Authors:  P E Shrout; J L Fleiss
Journal:  Psychol Bull       Date:  1979-03       Impact factor: 17.737

3.  Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis.

Authors:  P J Clements; P A Lachenbruch; S C Ng; M Simmons; M Sterz; D E Furst
Journal:  Arthritis Rheum       Date:  1990-08

4.  Reliability of skin score in scleroderma.

Authors:  A Harrison; J Lusk; M Corkill
Journal:  Br J Rheumatol       Date:  1993-02

5.  Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.

Authors:  P J Clements; E L Hurwitz; W K Wong; J R Seibold; M Mayes; B White; F Wigley; M Weisman; W Barr; L Moreland; T A Medsger; V D Steen; R W Martin; D Collier; A Weinstein; E Lally; J Varga; S R Weiner; B Andrews; M Abeles; D E Furst
Journal:  Arthritis Rheum       Date:  2000-11

6.  Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.

Authors:  P J Clements; P A Lachenbruch; J R Seibold; B Zee; V D Steen; P Brennan; A J Silman; N Allegar; J Varga; M Massa
Journal:  J Rheumatol       Date:  1993-11       Impact factor: 4.666

7.  Variability of skin scores and clinical measurements in scleroderma.

Authors:  J E Pope; M Baron; N Bellamy; J Campbell; S Carette; I Chalmers; P Dales; J Hanly; E A Kaminska; P Lee
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

8.  Is it possible to reduce observer variability in skin score assessment of scleroderma? The ad hoc International Group on the Assessment of Disease Outcome in Scleroderma.

Authors:  A Silman; M Harrison; P Brennan
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

9.  Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

Authors:  P Clements; P Lachenbruch; J Siebold; B White; S Weiner; R Martin; A Weinstein; M Weisman; M Mayes; D Collier
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

10.  D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.

Authors:  V D Steen; T A Medsger; G P Rodnan
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

View more
  34 in total

Review 1.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

2.  The correlation between durometer score and modified Rodnan skin score in systemic sclerosis.

Authors:  Ki Won Moon; Ran Song; Jin Hyun Kim; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Rheumatol Int       Date:  2011-07-19       Impact factor: 2.631

3.  Stem cells: HSCT for systemic sclerosis--swallows and summers.

Authors:  Alan Tyndall
Journal:  Nat Rev Rheumatol       Date:  2011-09-13       Impact factor: 20.543

Review 4.  Ultrasound in systemic sclerosis. A multi-target approach from joint to lung.

Authors:  Marwin Gutierrez; Carlos Pineda; Tomas Cazenave; Marco Piras; Gian Luca Erre; Antonella Draghessi; Rossella De Angelis; Walter Grassi
Journal:  Clin Rheumatol       Date:  2014-02-18       Impact factor: 2.980

5.  Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Philip J Clements; Yannick Allanore; Murray Baron; Lazlo Czirjak; Oliver Distler; Ivan Foeldvari; Masataka Kuwana; Marco Matucci-Cerinic; Maureen Mayes; Thomas Medsger; Peter A Merkel; Janet E Pope; James R Seibold; Virginia Steen; Wendy Stevens; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2017 Jan-Apr

6.  Correlation between circulating fibrocytes and dermal thickness in limited cutaneous systemic sclerosis patients: a pilot study.

Authors:  Barbara Ruaro; Stefano Soldano; Vanessa Smith; Sabrina Paolino; Paola Contini; Paola Montagna; Carmen Pizzorni; Andrea Casabella; Samuele Tardito; Alberto Sulli; Maurizio Cutolo
Journal:  Rheumatol Int       Date:  2019-05-06       Impact factor: 2.631

7.  The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.

Authors:  Thaschawee Arkachaisri; Soamarat Vilaiyuk; Suzanne Li; Kathleen M O'Neil; Elena Pope; Gloria C Higgins; Marilynn Punaro; Egla C Rabinovich; Margalit Rosenkranz; Daniel A Kietz; Paul Rosen; Steven J Spalding; Teresa R Hennon; Kathryn S Torok; Elaine Cassidy; Thomas A Medsger
Journal:  J Rheumatol       Date:  2009-10-15       Impact factor: 4.666

Review 8.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

9.  Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.

Authors:  Katharina Hanke; Claudia S Brückner; Cornelia Dähnrich; Dörte Huscher; Lars Komorowski; Wolfgang Meyer; Anthonia Janssen; Marina Backhaus; Mike Becker; Angela Kill; Karl Egerer; Gerd R Burmester; Falk Hiepe; Wolfgang Schlumberger; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-02-16       Impact factor: 5.156

10.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.